Alto on the mark again in depression

5 December 2023

Privately-held Californian company Alto Neuroscience has announced encouraging results from its Phase IIa study of ALTO-300 at the 62nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP).

The results demonstrate clinically meaningful improvements and favorable safety and tolerability in patients with major depressive disorder (MDD) when using ALTO-300, a drug from Alto’s Precision Psychiatry Platform with an undisclosed target.

"Our conviction in the promise of precision medicine for the brain is bolstered by these results"Alto’s other candidates at this stage of development, ALTO-100 and ALTO-202, have also impressed, with this the third positive Phase II readout.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK